ibusinesslines.com September 26, 2018

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) declared EPS of

27 April 2017, 04:04 | Kelvin Horton

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares have been recently spotted -45.95% away from the 52-week high, and 330.54% away from the 52-week low mark.

Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms. Oppenheimer Holdings analyst H. Singh now expects that the biotechnology company will earn $3.49 per share for the year, up from their previous forecast of $3.48.

In a statement issued on 04/24/2017 Vetr Inc. upped the price target of Sarepta Therapeutics Inc (NASDAQ:SRPT) to $37.67 stating a potential upside of 0.11%. Cowen and Company reaffirmed an outperform rating and set a $62.00 price objective on shares of Sarepta Therapeutics in a research report on Saturday, March 11th.

03/01/2017 - Sarepta Therapeutics, Inc. had its "buy" rating reiterated by analysts at Needham & Company. National Bank Of America De reported 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). The stock has "Neutral" rating by Piper Jaffray on Friday, January 15. Finally, Nomura initiated coverage on shares of Sarepta Therapeutics in a research report on Wednesday, March 1st. They set a buy rating and a $84.00 price objective on the stock. Out of 24 Wall Street analysts rating Sarepta Therapeutics, 16 give it "Buy", 1 "Sell" rating, while 7 recommend "Hold".

The stock's price switched up 18.58% 20-Days Simple Moving Average, added 17.66% from 50-Days Simple Moving Average and rose 5.99% from 200 Days Simple Moving Average. The overall volume in the last trading session was 3.28 million shares. The company has market cap of 2.06 billion GBP. Ameriprise Fincl reported 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). The analysts estimated EPS for the higher end at -0.55 and lower end at -1.34 while the year ago reported earnings per share was -0.8.

14 number of analysts have estimated the sales of the company for the quarter ending April 27, 2017, analysts estimated mean sale target of 27.08 million while high and low sale targets are estimated at 37.82 million and 20.17 million respectively. The business's quarterly revenue was up 333.6% compared to the same quarter previous year. During the same period in the prior year, the company posted ($1.44) EPS.

COPYRIGHT VIOLATION WARNING: This story was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & worldwide trademark & copyright law. The original version of this article can be accessed at https://transcriptdaily.com/2017/04/23/sarepta-therapeutics-srpt-outperform-rating-reaffirmed-at-robert-w-baird.html. If the average volume is low then the liquidity is low which means it is hard to buy or sell the stock as there are fewer buyers or sellers of the stock.

03/01/2017 - Instinet began new coverage on Sarepta Therapeutics, Inc. giving the company a "buy" rating. Jennison Associates LLC now owns 1,393,788 shares of the biotechnology company's stock worth $85,593,000 after buying an additional 647,030 shares in the last quarter. BlackRock Advisors LLC now owns 839,928 shares of the biotechnology company's stock worth $51,580,000 after buying an additional 697,122 shares in the last quarter. Lehman Financial Resources Inc. bought a new stake in Sarepta Therapeutics during the third quarter worth approximately $237,000. Investors have the ability to follow analyst projections in order to help compile valuable company information.

Sarepta is a biopharmaceutical company focused on the discovery and development of therapeutics for the treatment of rare, infectious and other diseases. The Company developed the drug eteplirsen for the treatment of Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease.

Other News

Trending Now

EU to exclude financial services from post-Brexit deal
Miller, who received a torrent of online abuse during her legal challenge, said the intimidation had not stopped. The launch saw Best for Britain unveil its three-point charter.

James Harden's leadership fuels revamped Houston Rockets to West semifinals
The Houston Rockets completed a gentleman's sweep of the Oklahoma City Thunder with a 105-99 home victory in Game 5. A new coach in Mike D'Antoni, who practically gave him a jet pack to go with a license to thrill.

UK's Labour pledges new Brexit strategy if it wins
Prime Minister May has said the United Kingdom could not remain part of the single market as it would mean not leaving the EU. Cabinet Office spokesman Lord Young rejected the idea of lowering the voting age and said it will stay at 18.

Islamic State, Taliban clash in Afghanistan, dozens killed
Late last month, other top ranking U.S. military officials spoke to the allegations, but discussed them with greater uncertainty. General in Afghanistan John Nicholson told reporters in a December Pentagon briefing. "This is a false narrative".

Jury gives death penalty to PA ambush killer
Frein's defense team argued their case for a life sentence by presenting mitigating circumstances to lessen Frein's culpability. His lawyers did not contest his guilt, focusing their efforts on trying to save his life during the penalty phase of the trial.

Asian shares retreat from highs after Trump tax plan
That growth, in turn, would prevent the plan from leaving the federal government short trillions of dollars of tax revenue. Stocks have been lifted by investor anticipation of big tax cuts as well as Trump's vow to cut red tape for businesses.

Trump's Approval Rating Hits 41 Percent In Latest CBS Poll
Even 29 percent of Democrats, who may disagree with Trump's agenda, believe he's holding true to his campaign promises. The poll also asked USA adults their thoughts on the Obama administration's alleged spying on the Trump campaign.